Suvorexant for Treatment of AUD and PTSD
NCT06679062
Recruiting
This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random assignment to receive placebo or suvorexant for an additonal 14 days. Post-randomization, participants will attempt to stop drinking for two weeks and will complete daily virtual diaries and study outco... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/16/2025
Locations: University of California - Los Angeles, Los Angeles, California +1 locations
Conditions: Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD), Insomnia
Register for Updates
CEUS Evaluation of Hydrocephalus in Neonates and Infants
NCT06693752
Recruiting
Hydrocephalus affects up to 2 out of every 500 births and results in long-term disability in up to 78% of those affected. The standard treatment of hydrocephalus is cerebrospinal fluid (CSF) diversion via placement of an invasive ventricular shunt to relieve elevated intracranial pressure (ICP). The clinical decision for CSF diversion is based on the ventricular size and clinical symptoms which are not robust indicators of brain health in neonatal hydrocephalus. The purpose of this study is to a... Read More
Gender:
ALL
Ages:
Between 1 minute and 18 months
Trial Updated:
07/16/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Hydrocephalus in Infants, Hydrocephalus Acquired
Register for Updates
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805
Recruiting
This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Birmingham, Alabama +59 locations
Conditions: HIV Infections
Register for Updates
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
NCT06704191
Recruiting
This phase Ib/II trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer. Chemotherapy drugs, such as bacillus Calmette-Guerin (BCG), gemcitabine, docetaxel, and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Standard of care chemotherapy for non-invasiv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Non-Muscle Invasive Bladder Carcinoma, Stage I Bladder Cancer AJCC V8, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Register for Updates
Paired Vagus Nerve Stimulation Mechanisms
NCT06716112
Recruiting
In this mechanistic study, 40 individuals with chronic stroke will be implanted with a small vagus nerve stimulation (VNS) device. The study will use a randomized, blinded, crossover design to deliver two conditions in six-week blocks: active VNS or sham VNS, each paired with upper extremity (UE) motor rehabilitation. Assessment visits will occur before and after each block, and will examine neural pathway strength, functional connectivity, and motor and non-motor behaviors. Investigators will t... Read More
Gender:
ALL
Ages:
Between 22 years and 79 years
Trial Updated:
07/16/2025
Locations: NYU Langone Health, New York, New York +1 locations
Conditions: Chronic Stroke
Register for Updates
A Study of NE3107 in Early Parkinson's
NCT06757010
Recruiting
The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are: * Will bezisterim decrease movement symptoms of Parkinson's disease? * What medical problems do participants ha... Read More
Gender:
ALL
Ages:
Between 45 years and 80 years
Trial Updated:
07/16/2025
Locations: Quest Research Institute, Farmington Hills, Michigan +3 locations
Conditions: Parkinsons Disease (PD)
Register for Updates
Light Therapy Device for Neonatal Intraventricular Hemorrhage Grade 3 and 4
NCT06797219
Recruiting
The primary purpose of this study is to serve as a pilot study of the EFIL device treatment feasibility of IVH grades 3,4 to guide development of a larger trial. Primary outcomes will assess the following: safety of intervention, recruitment and consent process, acceptability of intervention by parents, retention rates, selection of most appropriate outcome measures, provide sample size estimates for a larger trial, increase the researchers\' experience with the study intervention. A complet... Read More
Gender:
ALL
Ages:
Between 0 days and 1 month
Trial Updated:
07/16/2025
Locations: Rutgers - New Jersey Medical School / University Hospital, Newark, New Jersey +1 locations
Conditions: Intraventricular Hemorrhage of Prematurity, Hydrocephalus
Register for Updates
Investigating Metabolic and Psychological Adaptations in a Clinical Trial
NCT06800794
Recruiting
This study aims to explore how food insecurity, a lack of consistent access to enough food, may lead to changes in the body that make it harder to lose weight. The investigators are testing whether providing women experiencing food insecurity with a stable, healthy, and personalized meal plan can improve their metabolism and reduce their motivation to eat unhealthy foods. The hypothesis is that addressing food insecurity with a predictable diet can lower a person's respiratory quotient (a measur... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/16/2025
Locations: Farber Hall G56, Buffalo, New York
Conditions: Obesity and Type 2 Diabetes
Register for Updates
GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women
NCT06813261
Recruiting
The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enh... Read More
Gender:
FEMALE
Ages:
Between 45 years and 65 years
Trial Updated:
07/16/2025
Locations: The Buck Institute for Research on Aging, Novato, California
Conditions: Postmenopause, Metabolism, Geroscience
Register for Updates
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
NCT06834126
Recruiting
This phase I trial studies the side effects and best dose of papaverine (PPV) when given together with radiation therapy (RT) and tests how well it works in treating patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). PPV is an enzyme inhibitor, and it may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. RT uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Giving PPV wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Register for Updates
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
NCT06836063
Recruiting
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/16/2025
Locations: Advanced Research Center, Inc., Anaheim, California +12 locations
Conditions: Major Depressive Disorder (MDD)
Register for Updates
Virtual Nephrologist
NCT06841016
Recruiting
To develop, pilot, and refine a virtual healthcare agent that will educate patients with advanced chronic kidney disease and their caregivers about kidney transplantation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Chronic Kidney Disease(CKD)
Register for Updates